Antisense modulation of caspase 3 expression
First Claim
Patent Images
1. The antisense co pound up to 30 nucleobases in length targeted to a nucleic acid molecules encoding caspase 3, wherein said antisense compound comprises at least an 8 nucleobase portion of SEQ ID NO:
- 18, 19, 20, 23, 24, 25, 26, 27, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 44, 46, 47, 48, 50, 51, 54, 55, 56, 57, 59, 61, 63, 64, 65, 67, 68, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 89, 91, 92, 94, 95,96, 97, 98, 101, 102, 103, 106, 107, 108, 113, 114, 116, 117, 118, 119, 120, 121, 122, 124, 126, 127, 129, 131, 133, 140, 142, 143, 146, 150, 151, 154, 159, 160, 164, 167 or 169 and wherein said antisense compound specifically hybridizes with and inhibits the expression of said nucleic acid molecule encoding caspase 3.
2 Assignments
0 Petitions
Accused Products
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of caspase 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 3. Methods of using these compounds for modulation of caspase 3 expression and for treatment of diseases associated with expression of caspase 3 are provided.
-
Citations
12 Claims
-
1. The antisense co pound up to 30 nucleobases in length targeted to a nucleic acid molecules encoding caspase 3, wherein said antisense compound comprises at least an 8 nucleobase portion of SEQ ID NO:
- 18, 19, 20, 23, 24, 25, 26, 27, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 44, 46, 47, 48, 50, 51, 54, 55, 56, 57, 59, 61, 63, 64, 65, 67, 68, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 89, 91, 92, 94, 95,96, 97, 98, 101, 102, 103, 106, 107, 108, 113, 114, 116, 117, 118, 119, 120, 121, 122, 124, 126, 127, 129, 131, 133, 140, 142, 143, 146, 150, 151, 154, 159, 160, 164, 167 or 169 and wherein said antisense compound specifically hybridizes with and inhibits the expression of said nucleic acid molecule encoding caspase 3.
- View Dependent Claims (2, 3, 4, 6, 8, 9, 12)
-
5. The antisense compound of claim 5 wherein the modified sugar moiety is a 2′
- -O-methoxyethyl sugar moiety.
-
7. The antisense compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
- 10. The pharmaceutical composition of claim 10 further comprising a colloidal dispersion system.
Specification